These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15891407)

  • 21. The use of MRI as an outcome measure in clinical trials.
    Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D
    Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple sclerosis: clinical trial design 2019.
    Pardini M; Cutter G; Sormani MP
    Curr Opin Neurol; 2019 Jun; 32(3):358-364. PubMed ID: 30950845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of multiple sclerosis: current trials and future options.
    Noseworthy JH
    Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.
    Bar-Zohar D; Agosta F; Goldstaub D; Filippi M
    Mult Scler; 2008 Jul; 14(6):719-27. PubMed ID: 18424478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials.
    Martinelli Boneschi F; Rovaris M; Comi G; Filippi M
    Mult Scler; 2004 Aug; 10(4):341-7. PubMed ID: 15327027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
    Fernández Ó
    Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.
    Goodkin DE
    West J Med; 1994 Sep; 161(3):292-8. PubMed ID: 7975569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mode of action and clinical studies with fumarates in multiple sclerosis.
    Salmen A; Gold R
    Exp Neurol; 2014 Dec; 262 Pt A():52-6. PubMed ID: 24568735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B; Hartung HP
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials.
    Barkhof F; Filippi M; Miller DH; Tofts P; Kappos L; Thompson AJ
    J Neurol; 1997 Feb; 244(2):76-84. PubMed ID: 9120500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials.
    Truyen L; Barkhof F; Tas M; Van Walderveen MA; Frequin ST; Hommes OR; Nauta JJ; Polman CH; Valk J
    Mult Scler; 1997 Jan; 2(6):283-90. PubMed ID: 9065919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
    Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
    BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis.
    Janardhan V; Bakshi R
    Arch Neurol; 2000 Oct; 57(10):1485-91. PubMed ID: 11030802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current treatment for multiple sclerosis].
    Papeix C; Lubetzki C; Lyon-Caen O
    Presse Med; 2010 Mar; 39(3):381-8. PubMed ID: 20106633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced magnetic resonance imaging in multiple sclerosis.
    Filippi M
    Mult Scler; 2000 Oct; 6(5):320-6. PubMed ID: 11064441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.